Nov 20, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer's Disease Conference
CAMBRIDGE, Mass., Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) today announced upcoming scientific presentations at the 18th Clinical Trials on Alzheimer's Disease ( CTAD ) Conference, taking place December 1-4 in San Diego.
Nov 18, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer
More than 20 years of financial and operational leadership in biopharma, including $170M+ in capital raised, global commercialization experience, and a proven track record scaling companies from preclinical to clinical milestones More than 20 years of financial and operational leadership in ...
Nov 18, 2025 • Benzinga
SOMEWHAT-BULLISH
Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer - Akari Therapeutics ( NASDAQ:AKTX )
TAMPA and LONDON, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- Akari Therapeutics, Plc ( NASDAQ:AKTX ) , an oncology biotechnology company developing novel payloads for antibody drug conjugates ( ADCs ) , today announced the appointment of Kameel D. Farag as its Interim Chief Financial Officer who joined ...
Nov 17, 2025 • Benzinga
NEUTRAL
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy - Ionis Pharmaceuticals ( NASDAQ:IONS ) , Biogen ( NASDAQ:BIIB )
Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved 12mg dose regimen1 Final European Commission decision expected in January 2026
Nov 14, 2025 • GlobeNewswire
NEUTRAL
Biogen Completes Acquisition of Alcyone Therapeutics
CAMBRIDGE, Mass., Nov. 14, 2025 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CNS therapy delivery solutions, such as the ThecaFlex DRx™ drug delivery system.
Nov 14, 2025 • Benzinga
NEUTRAL
Biogen Completes Acquisition of Alcyone Therapeutics - Ionis Pharmaceuticals ( NASDAQ:IONS ) , Biogen ( NASDAQ:BIIB )
CAMBRIDGE, Mass., Nov. 14, 2025 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( NASDAQ:BIIB ) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CNS therapy delivery solutions, such as the ThecaFlex DRx™ drug delivery system.